Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gum graft material could reduce pain for receding gums

NCT ID NCT03162016

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new material called Mucoderm, made from donated animal tissue, to treat receding gums. It compared it to the standard treatment, which uses a small piece of tissue from the patient's own palate. The goal was to see if Mucoderm could cover exposed tooth roots just as well but with less pain. Twelve patients with gum recession on both sides of their mouth received one treatment on each side, and the results were compared after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mucoderm (xenogenic acellular dermal matrix)
What this could lead to
If successful, this could offer a less painful alternative to traditional gum grafting for treating receding gums.
What could go wrong
This is a very small, early study with only 12 patients, so results may not apply to everyone. The new material may not cover roots as well as the standard graft.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jun 2017

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \> 45 years, postmenopausal women (ie with amenorrhea for more than a year). * Subject with bilateral Miller class I or II recessions defects * non smoking patients * patients having read and understood the information note on the study and signed the informed consent form. * patients affiliated to the social security system. Exclusion Criteria: * Patient with absolute contra-indication for dental surgery: valvular heart disease at risk of infectious endocarditis, recent myocardal (≤ 12 months), organ transplants, recent placement of a coronary stent (≤ 12 months), transient ischemic attacks recurrent, cardiovascular instability, uncontrolled epilepsy, rheumatic fever. * Patient with metabolic bone disease (Paget's disease, osteomalacia, osteogenesis imperfecta) * Patient with an ASA score ≥ 3. * Patient with absolute contra-indication to dental surgery * Patient with severe hematologic disease * Patient with I or type II diabetes * Patients with previous or current acute illness or severe chronic cardiovascular, renal, hepatic, gastrointestinal, allergic, endocrine, neuro-psychiatric, considered by the investigator to be incompatible with the conduct of the study. * Patients treated with retinoids, oral bisphosphonates, oral anticoagulants or anticonvulsants. * Patient have or have had cancer of the upper aerodigestive tract treated by radiotherapy. * Patient taking a steroidal or non-steroidal anti-inflammatory, anti-cancer or immunosuppressive chemotherapy in the last 6 months. * Patient monitoring considered difficult by the investigator. * Patient with poor oral hygiene incompatible with oral surgery. * Patients with periodontal disease unstabilized * Patient with oral dermatitis or adverse occlusion. * Patient with an acute or chronic infection of the surgical site (osteomyelitis). * Patient with a known allergy to collagen * Patient with autoimmune disease * Patient with a linguistic or mental incapacity to understand information * Patient younger than 45 years old * Patient trust under curatorship or judicial protection * Patients aged over 45 premenopausal. * Patient participating in another clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gingival recession are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Nice

    Nice, France, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.